RxDoctor Payments Data

Jeffrey Larsen, MD

Internal Medicine · River Falls, WINPI 1104819622

Payments from drug & device makers

$521in general payments, 2019–2025

Across 22 payments — averaging $23.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$127
  • Novo Nordisk$126
  • Johnson & Johnson$68
  • Boehringer Ingelheim$60
  • Boston Scientific$60
  • AstraZeneca$32
  • plus $47 from 3 others

What the payments were for

  • Food & beverage$521100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$521 in reported general payments places this provider in the 85th percentile of 1,411 internal medicine providers in Wisconsin.

See all internal medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$133,463
Medicare patients
387
Services billed
2,569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide100$125,803
XareltoRivaroxaban94$92,768
EliquisApixaban87$91,810
JardianceEmpagliflozin68$70,313
TrulicityDulaglutide36$42,097
Xultophy 100-3.6Insulin Degludec/Liraglutide13$21,779
FarxigaDapagliflozin Propanediol18$17,277
RybelsusSemaglutide13$11,792
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,654
Breo ElliptaFluticasone/Vilanterol23$9,185
DuleraMometasone/Formoterol22$7,119
Atorvastatin Calcium594$6,667
Metoprolol Succinate243$4,646
Levothyroxine Sodium209$3,504
Fluticasone-SalmeterolFluticasone Propion/Salmeterol27$3,436

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus$126$159,373126 claims
Johnson & JohnsonXarelto$68$92,76894 claims
PfizerEliquis$16$91,81087 claims
Boehringer IngelheimJardiance$60$70,31368 claims
AstraZenecaFarxiga$32$17,27718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,411 internal medicine providers in Wisconsin.

Other internal medicine in River Falls

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →